In This Article:
Harvard Bioscience (NASDAQ:HBIO) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$22.0m (down 13% from 3Q 2023).
-
Net loss: US$4.80m (loss widened by 288% from 3Q 2023).
-
US$0.11 loss per share (further deteriorated from US$0.029 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Harvard Bioscience Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 83%.
Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are up 7.1% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Harvard Bioscience that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.